on by society. The neurodiversity movement does not believe that autism can or must be treated, 3 but this belief must not limit eff orts to make advancements in the diagnosis and treatment of autism. People with autism come across defi cits in a wide range of issues ranging from communication and social interaction to cognitive functions, problems with feeding, hyposensitivity or hypersensitivity to stimuli, and even self-harming behaviour. As severity increases, activities of daily living are restricted. For this reason, people with autism and their family members seek interventions such as speech therapy, sensory integration therapy, and applied behaviour analysis, which help to mitigate their diffi culties to a large extent. 4 People in resource-constrained settings are more likely to struggle as their health system is already burdened with different conflicting priorities. Therefore, expansion-both in quantity and geographically-of these services and interventions closer to those in need is necessary. Although the Editorial emphasises the need to take pride in diversity in neural structures, it does not address much about the suff ering associated with these diverse conditions.
Everyone is diff erent neurologically and such is the case with autism. Society should respect the human rights of people with autism, and efforts should be made to provide them with access to the best available services and help them to live a decent life. The primary focus of all stakeholders should be on raising public awareness of autism worldwide. By abandoning their no-cure advocacy, the neurodiversity movement will not only come together with the scientifi c community and health professionals who can help people with autism to make informed choices about treatment and therapeutic measures, 5 but also embrace the large part of the autistic community who seek a cure while taking pride in being neurodiverse.
vascular. "Vascular lesions affecting central nervous system" have been in the diseases of the vascular system chapter since ICD-7. The decisions were made available on the ICD web platform in August, 2016.
WHO will release the 2016 version of the ICD-11 for country comments during the ICD revision conference in Tokyo, Japan, held Oct 12-14, 2016. The results of country fi eld testing and further refi nements should result in the release of the ICD-11 for country implementation in 2018. 
Pride in autistic diversity: against treatment or for inclusion?
The Lancet Editorial (June 18, p 2479) 1 invokes the theme of neurodiversity and regards autism as a condition rather than a disorder, thus respecting the identity of those with autism. Autism is a broad spectrum of disorders, and its severity varies among people. People with autism are considered diff erently normal, and can contribute to society like any other individual. However, evidence on autism is scarce, and the variety of the condition presents a challenge for the scientifi c community working to find its causes and cure. 2 Sadly, the neurodiversity movement, whose proponents and campaigners are mostly people with high-functioning autism or Asperger's syndrome and their family members, 3 is not able to embrace the majority of the autistic community who are still looked down
New poliovirus vaccine schedules
In their randomised controlled trial, Edwin J Asturias and colleagues (July 9, p 158) 1 reported a robust humoral immune response after three doses of bivalent type 1 and 3 oral poliovirus vaccine (bOPV) combined with zero, one, or two doses of inactivated poliovirus vaccine (IPV), confirming that bOPV is highly immunogenic when administered either with or without IPV. In their study, 6-week-old fullterm Latin American infants due for their first polio vaccinations were randomly assigned by permuted block randomisation to fi ve schedules. We agree that risk mitigation measures need to be taken against type 2 poliovirus, especially in light of the global supply shortage of IPV.
However, the orders of vaccination schedules in the study were diff erent from the orders recommended by WHO (introduction of IPV followed by OPV). 2 In countries preparing for the switch from OPV to IPV, these IPV fi rst schedules could have an added advantage of helping to reduce the risk of vaccine-associated paralytic polio myelitis, as around 50% of cases recorded were related to the first Getty Images
